Regeneron Pharmaceuticals, Inc. or Novavax, Inc.: Who Leads in Yearly Revenue?

Biotech Revenue Race: Regeneron vs. Novavax from 2014-2023

__timestampNovavax, Inc.Regeneron Pharmaceuticals, Inc.
Wednesday, January 1, 2014306590002819557000
Thursday, January 1, 2015362500004103728000
Friday, January 1, 2016153530004860427000
Sunday, January 1, 2017311760005872227000
Monday, January 1, 2018342880006710800000
Tuesday, January 1, 2019186620007863400000
Wednesday, January 1, 20204755980008497100000
Friday, January 1, 2021114629000016071700000
Saturday, January 1, 2022159895100012172900000
Sunday, January 1, 202355638200013117200000
Monday, January 1, 202414202000000
Loading chart...

Igniting the spark of knowledge

A Tale of Two Biotechs: Revenue Race from 2014 to 2023

In the dynamic world of biotechnology, Regeneron Pharmaceuticals, Inc. and Novavax, Inc. have been pivotal players. Over the past decade, Regeneron has consistently outpaced Novavax in terms of revenue. From 2014 to 2023, Regeneron's revenue surged by over 360%, peaking at approximately $13.1 billion in 2023. In contrast, Novavax, despite its significant growth, reached a high of around $1.6 billion in 2022, marking a 5,100% increase from its 2014 revenue.

The year 2021 was particularly noteworthy, with Regeneron achieving its highest revenue of $16.1 billion, driven by its innovative treatments and strategic partnerships. Meanwhile, Novavax's revenue spike in 2021 and 2022 can be attributed to its COVID-19 vaccine efforts. This revenue comparison highlights the contrasting growth trajectories and strategic focuses of these two biotech giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025